These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37291022)

  • 1. Cost-effectiveness of routine annual influenza vaccination by age and risk status.
    Kim DeLuca E; Gebremariam A; Rose A; Biggerstaff M; Meltzer MI; Prosser LA
    Vaccine; 2023 Jun; 41(29):4239-4248. PubMed ID: 37291022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.
    Prosser LA; Lavelle TA; Fiore AE; Bridges CB; Reed C; Jain S; Dunham KM; Meltzer MI
    PLoS One; 2011; 6(7):e22308. PubMed ID: 21829456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
    Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
    BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of seasonal influenza vaccination in WHO-defined high-risk populations in Bangladesh.
    Hassan MZ; Jubayer Biswas MAA; Shirin T; Rahman M; Chowdhury F; Azziz-Baumgartner E; Davis WW; Hussain M
    J Glob Health; 2024 Jul; 14():04126. PubMed ID: 39024624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
    Edoka I; Kohli-Lynch C; Fraser H; Hofman K; Tempia S; McMorrow M; Ramkrishna W; Lambach P; Hutubessy R; Cohen C
    Vaccine; 2021 Jan; 39(2):412-422. PubMed ID: 33272702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of influenza vaccination during pregnancy in Japan.
    Hoshi SL; Shono A; Seposo X; Okubo I; Kondo M
    Vaccine; 2020 Oct; 38(46):7363-7371. PubMed ID: 33020012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 10. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate.
    Nham E; Seong H; Hyun H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim E; Choi L; Lee JM; Song JY
    Hum Vaccin Immunother; 2023 Dec; 19(3):2266233. PubMed ID: 37964587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study.
    Ding H; Huang J; Ngai CH; Sun Q; Kwok KO; Wang HH; Chong M; Wong MC
    Vaccine; 2022 Feb; 40(9):1282-1288. PubMed ID: 35094867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands.
    Naber SK; Bruijning-Verhagen PCJL; de Hoog MLA; van Giessen A
    Vaccine; 2020 Apr; 38(17):3387-3396. PubMed ID: 32115297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of seasonal influenza vaccination of children in China: a modeling analysis.
    Wang Q; Jin H; Yang L; Jin H; Lin L
    Infect Dis Poverty; 2023 Oct; 12(1):92. PubMed ID: 37821942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness.
    Prosser LA; O'Brien MA; Molinari NA; Hohman KH; Nichol KL; Messonnier ML; Lieu TA
    Pharmacoeconomics; 2008; 26(2):163-78. PubMed ID: 18198935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.